Boston Scientific Corporation $BSX Shares Sold by First Citizens Bank & Trust Co.

First Citizens Bank & Trust Co. trimmed its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 20.4% during the second quarter, HoldingsChannel reports. The institutional investor owned 5,201 shares of the medical equipment provider’s stock after selling 1,332 shares during the quarter. First Citizens Bank & Trust Co.’s holdings in Boston Scientific were worth $559,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BSX. Brighton Jones LLC lifted its position in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after buying an additional 226 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Boston Scientific by 17.2% during the first quarter. GAMMA Investing LLC now owns 25,554 shares of the medical equipment provider’s stock valued at $2,578,000 after purchasing an additional 3,745 shares during the period. Spire Wealth Management raised its stake in shares of Boston Scientific by 15.9% during the first quarter. Spire Wealth Management now owns 10,630 shares of the medical equipment provider’s stock valued at $1,072,000 after purchasing an additional 1,456 shares during the period. Golden State Wealth Management LLC increased its stake in shares of Boston Scientific by 37.0% in the first quarter. Golden State Wealth Management LLC now owns 1,674 shares of the medical equipment provider’s stock worth $169,000 after buying an additional 452 shares during the last quarter. Finally, Perigon Wealth Management LLC increased its stake in shares of Boston Scientific by 7.9% in the first quarter. Perigon Wealth Management LLC now owns 13,532 shares of the medical equipment provider’s stock worth $1,365,000 after buying an additional 996 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

Shares of BSX opened at $101.08 on Friday. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50. The company has a market cap of $149.78 billion, a price-to-earnings ratio of 54.06, a price-to-earnings-growth ratio of 2.34 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The firm has a fifty day moving average of $101.14 and a 200-day moving average of $102.08.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. The company had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on BSX shares. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. Robert W. Baird lifted their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. UBS Group boosted their target price on shares of Boston Scientific from $135.00 to $140.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Erste Group Bank lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $123.77.

Insider Buying and Selling

In related news, Director Yoshiaki Fujimori sold 2,901 shares of the company’s stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director owned 2,081 shares of the company’s stock, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $17,561,336.74. This trade represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 170,214 shares of company stock valued at $17,548,337 over the last 90 days. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.